BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Saruparib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Saruparib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06713369-2090@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Saruparib: Phase 1 readout est. (NCT06713369)
DESCRIPTION:Saruparib\, phase 1.\nStudy: AZD5305 hADME in Patients With Adv
 anced Solid Malignancies\nEstimated primary completion: 31 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/saruparib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06713369
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04644068-2090@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Saruparib: Phase 1/2 readout est. (NCT04644068)
DESCRIPTION:Saruparib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer A
 gents in Patients With Advanced Solid Malignancies\nEstimated primary comp
 letion: 28 May 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 saruparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04644068
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04005690-2090@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Saruparib: Phase 1 readout est. (NCT04005690)
DESCRIPTION:Saruparib\, phase 1.\nStudy: Targeted Pathway Inhibition in Pat
 ients With Pancreatic Cancer\nEstimated primary completion: 1 June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/saruparib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04005690
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05123482-2090@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Saruparib: Phase 1/2 readout est. (NCT05123482)
DESCRIPTION:Saruparib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Phase I/IIa Study of AZD8205 Given Alone or Combined\, in Participa
 nts With Advanced/Metastatic Solid Malignancies\nEstimated primary complet
 ion: 29 September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/saruparib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05123482
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06120491-2090@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Saruparib: Phase 3 readout est. (NCT06120491)
DESCRIPTION:Saruparib\, phase 3\, Prostate Cancer.\nStudy: Saruparib (AZD53
 05) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer
  Receiving Physician's Choice New Hormonal Agents\nEstimated primary compl
 etion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/saruparib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06120491
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797168-2090@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20280804
DTEND;VALUE=DATE:20280805
SUMMARY:Saruparib: Phase 1/2 readout est. (NCT05797168)
DESCRIPTION:Saruparib\, phase 1/2.\nStudy: Phase I/IIa Study of AZD5335 as 
 Monotherapy and Combination Therapy in Participants With Solid Tumors\nEst
 imated primary completion: 4 August 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/saruparib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05797168
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769126-2090@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Saruparib: Phase 2 readout est. (NCT06769126)
DESCRIPTION:Saruparib\, phase 2.\nStudy: Using Biomarker Tests to Select an
 d Test New\, Personalized Treatments for Extensive Stage Small Cell Lung C
 ancer\, PRISM Study\nEstimated primary completion: 31 December 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/saruparib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06769126
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07832630-2090@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Saruparib: Phase 2 readout est. (NCT07832630)
DESCRIPTION:Saruparib\, phase 2.\nStudy: Saruparib in HRDsig+ Solid Tumors\
 nEstimated primary completion: 1 November 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/saruparib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07832630
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380751-2090@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Saruparib: Phase 3 readout est. (NCT06380751)
DESCRIPTION:Saruparib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStud
 y: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy\, Compa
 red With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in H
 R-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplified)\, BRCA1\, 
 BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary completion: 18
  December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sarup
 arib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06380751
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446855-2090@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20300329
DTEND;VALUE=DATE:20300330
SUMMARY:Saruparib: Phase 1/2 readout est. (NCT07446855)
DESCRIPTION:Saruparib\, phase 1/2.\nStudy: Study of AZD4956 as Monotherapy 
 and in Combination With Anti-Cancer Agents in Participants With Advanced/M
 etastatic Homologous Recombination Deficient Solid Tumours\nEstimated prim
 ary completion: 29 March 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/saruparib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07446855
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05367440-2090@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20310411
DTEND;VALUE=DATE:20310412
SUMMARY:Saruparib: Phase 1/2 readout est. (NCT05367440)
DESCRIPTION:Saruparib\, phase 1/2\, Prostate Cancer.\nStudy: Study of AZD53
 05 When Given in Combination With New Hormonal Agents in Patients With Met
 astatic Prostate Cancer\nEstimated primary completion: 11 April 2031. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/saruparib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05367440
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07711002-2090@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20310530
DTEND;VALUE=DATE:20310531
SUMMARY:Saruparib: Phase 3 readout est. (NCT07711002)
DESCRIPTION:Saruparib\, phase 3\, Prostate Cancer.\nStudy: Saruparib in Com
 bination With Physician's Choice of ARPI in Patients With mHSPC Previously
  Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression 
 and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)\nEstimated primary completion: 30 May 
 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/saruparib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07711002
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952803-2090@assetmemo.bio
DTSTAMP:20261121T004057Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Saruparib: Phase 3 readout est. (NCT06952803)
DESCRIPTION:Saruparib\, phase 3\, Prostate Cancer.\nStudy: A Study of Metas
 tases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT i
 n Men With High-risk Prostate Cancer With a BRCA Mutation\nEstimated prima
 ry completion: 31 March 2033. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/saruparib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06952803
URL:https://assetmemo.bio/drug/saruparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
